Saturday 17 October 2026 Export VERU’s income statement to Excel — free account

Veru Inc.

In the quarter to June 2026, EPS grew 40.0% and free cash flow was flat, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three; insiders bought in the last twelve months.

2.30 0.14 −5.74%

Follow VERU

Alert me

Market cap: $41.6M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 5/9
Altman Z: −5.84
Beneish M: −3.38
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 34.97%

Capital & Financial Ratios $m

Market Cap 41.61

Revenue 24.88

Net Income (13.61)

Free Cash Flow (26.04)

Net Debt (25.79)

Current Ratio 4.42

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.38)

P/S ratio 2.13

P/B ratio 1.87

Past 5Y EPS Growth —

This Y EPS Growth 47.96%

Next Y EPS Growth (2.89%)

Next Y revenue growth (94.82%)

Next 5Y EPS Growth 33.14%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.25%

10-year low 10-year high

P/B against its own 10 years 26.50%

10-year low 10-year high

EV/Sales against its own 10 years 9.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	10	26	18	26
Receivables	5	4	—	—
Inventory	7	4	—	—
Other	—	—	—	—
	23	35	19	27

	2023	2024	2025	Q'26
Payables	13	2	3	2
ST’ Debt	—	—	—	—
Other	1	1	—	—
	18	12	8	6

Compound Annual Growth %

	10y	5y	3y
Sales	(3.65%)	(11.89%)	(34.92%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(5.75%)	(9.45%)	(39.50%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	—	—	—	—	—
’24	—	4	4	13	17
’23	3	7	3	4	16
’22	14	13	10	3	39
’21	15	13	18	16	61
’20	11	10	10	12	43
’19	6	7	10	9	32

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(6)	(9)	(5)	—	—
’25	(11)	(8)	(5)	(5)	(30)
’24	(6)	(6)	(6)	(4)	(22)
’23	(35)	(26)	(18)	(9)	(88)
’22	(9)	(4)	(14)	(21)	(48)
’21	1	(3)	(13)	(1)	(16)
’20	(3)	(2)	3	0	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(6)	(9)	(5)	—	—
’25	(11)	(8)	(5)	(5)	(30)
’24	(6)	(6)	(6)	(4)	(22)
’23	(35)	(26)	(18)	(10)	(89)
’22	(9)	(4)	(14)	(21)	(48)
’21	1	(3)	(13)	(1)	(16)
’20	(3)	(2)	3	0	(2)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.26)	(0.12)	(0.30)	—	—
’25	(0.60)	(0.50)	(0.50)	0.10	(1.55)
’24	(0.80)	(0.70)	(0.70)	(0.60)	(2.80)
’23	(4.60)	(4.80)	(1.42)	(2.60)	(11.00)
’22	(0.80)	(1.80)	(2.80)	(5.10)	(10.50)
’21	2.30	(0.40)	(0.30)	(0.50)	0.90
’20	(0.50)	(0.10)	(0.50)	(1.70)	(2.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.20	9.00	11.50	11.80	23.00	57.20	43.40	6.40	3.60	2.10	Analyst estimates 2026–2028 Powerpack
	High	27.50	30.00	23.70	34.20	114.50	245.70	245.50	65.70	19.20	14.20
People
People	Employees	156	175	171	386	339	252	233	189	210	20
	Revenue/emp, $m	0.14	0.08	0.09	0.08	0.13	0.24	0.17	0.09	0.08	0.00
Income, $m
Income, $m	Revenue	22	14	16	32	43	61	39	16	17	—
	Gross margin, %	60.33	51.40	55.30	68.10	72.28	78.24	77.73	46.43	34.67	—
	EBT	3	(9)	(23)	(12)	(20)	4	(84)	(93)	(35)	(16)
	EBT margin, %	12.72	(63.00)	(145.43)	(38.74)	(47.08)	6.96	(212.95)	(568.65)	(208.81)	0.00
	Net income	0	(7)	(24)	(12)	(19)	7	(84)	(93)	(38)	(23)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	7.72	3.94	2.95	5.02	6.38	8.03	4.91	1.92	1.25	0.00
	Earnings	0.10	(2.50)	(4.40)	(1.90)	(2.80)	1.00	(10.50)	(11.00)	(2.80)	(1.55)
	Cash flow	(0.60)	0.28	(2.14)	(0.87)	(0.29)	(2.04)	(5.93)	(10.36)	(1.61)	(2.05)
	Capex	0.00	(0.04)	(0.01)	(0.02)	(0.02)	(0.05)	(0.09)	(0.08)	(0.01)	0.00
	Free cash flow	(0.60)	0.25	(2.15)	(0.88)	(0.30)	(2.09)	(6.02)	(10.44)	(1.62)	(2.05)
	Book value	11.84	13.99	5.47	5.11	4.51	19.97	10.33	2.32	2.40	1.25
	Shares, m	3	3	5	6	7	8	8	8	13	15
Valuation, ×
Valuation, ×	P/E	108.73	0.00	0.00	0.00	0.00	65.62	0.00	0.00	0.00	—
	P/S	1.58	5.76	4.45	4.30	4.11	10.62	23.45	3.81	4.17	—
	P/B	1.03	1.62	2.39	4.23	5.81	4.27	11.15	3.15	3.21	—
	EV/Sales	1.47	5.52	4.80	4.36	3.98	8.68	21.50	3.41	3.27	—
	EV/FCF	(18.94)	88.72	(6.57)	(24.79)	(83.25)	(33.33)	(17.54)	(0.63)	(3.69)	—
Cash, $m
Cash, $m	Operating cash flow	(2)	1	(12)	(5)	(2)	(16)	(48)	(88)	(22)	(30)
	Capex	0	0	0	0	0	0	(1)	(1)	0	0
	Free cash flow	(2)	1	(12)	(6)	(2)	(16)	(48)	(89)	(22)	(30)
Balance, $m
Balance, $m	Working capital	13	5	(2)	3	12	136	65	5	23	11
	Total debt	—	—	9	8	6	14	16	14	—	—
	Net debt	(2)	(3)	6	2	(8)	(122)	(80)	(10)	(26)	(18)
	Shareholders’ equity	34	48	29	32	30	152	83	20	32	18
Returns, %
Returns, %	ROA	0.91	(18.31)	(46.13)	(23.54)	(36.08)	6.44	(53.61)	(100.50)	(68.45)	(50.36)
	ROIC	5.98	(11.75)	(37.15)	(11.72)	(41.21)	27.09	(2,001.85)	(583.07)	(339.52)	(120,852.54)
	ROE	1.03	(20.88)	(61.43)	(38.88)	(60.77)	8.11	(71.50)	(181.80)	(145.40)	(89.74)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2024 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SER Serina Therapeutics, Inc.	$45.5M	— (loss-making)	— (loss-making)	+2,500.00% (above 0%: growing)	n/m	−76.82% (below 0%: shrinking)	100.00%	0.00%	Compare
ANVS Annovis Bio, Inc.	$44.8M	— (loss-making)	—	—	n/m	−329.18% (below 0%: shrinking)	—	0.00%	Compare
ALDX Aldeyra Therapeutics, Inc.	$44.5M	— (loss-making)	—	—	n/m	+46.09% (above 0%: growing)	0.00%	0.00%	Compare
CELU Celularity, Inc.	$43.2M	— (loss-making)	— (loss-making)	−66.34% (below 0%: shrinking)	n/m	+148.35% (above 0%: growing)	62.25%	(263.47%)	Compare
DWTX Dogwood Therapeutics, Inc	$42.5M	— (loss-making)	—	—	n/m	+10.31% (above 0%: growing)	—	0.00%	Compare
SGMOQ Sangamo Therapeutics, Inc.	$41.9M	— (loss-making)	— (loss-making)	−77.60% (below 0%: shrinking)	n/m	+26.21% (above 0%: growing)	100.00%	(2,215.40%)	Compare
VERU Veru Inc.	$41.6M	— (loss-making)	— (loss-making)	+287.06% (above 0%: growing)	n/m	+0.27% (above 0%: growing)	34.92%	0.00%
TIL Instil Bio, Inc.	$41.6M	— (loss-making)	—	—	n/m	+68.62% (above 0%: growing)	0.00%	0.00%	Compare
GRCE Grace Therapeutics, Inc.	$41.0M	— (loss-making)	— (loss-making)	+5,127.27% (above 0%: growing)	n/m	−78.85% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$42.8M	—	—	+1,216.83%	—	+18.26%	31.13%	0.00%

All 614 Biotechnology stocks →

Veru Inc. (VERU) key facts

Veru Inc. (VERU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VERU traded at $2.30, a market capitalization of $41.6 million.
Return on equity was −89.7% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −5.84 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.